Current Indian Science

Current Indian Science

Editor-in-Chief

ISSN (Print): 2210-299X
ISSN (Online): 2210-3007

Back Subscribe
Research Article Section: Medicinal Chemistry

Computational Molecular Docking and In-Silico, ADMET Prediction Studies of Quinoline Derivatives as EPHB4 Inhibitor

Author(s): Ganesh S. Mhaske*orcid of author, Sanket R. Thorat, Varun S. Pawar, Ravindra S. Pawar, Sarvesh R. Jambhulkar and Omkar A. Ghumre

Volume 2, 2024

Published on: 07 March, 2024

Article ID: e2210299X265033

Pages: 16

DOI: 10.2174/012210299X265033240116113623

open_access

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Background: The creation and development of novel chemical entities is made possible by numerous computer-aided drug design techniques. The ability to visualize the ligand-target interaction and forecast the important holding pocket locations and affinities of ligands to their intended macromolecules is made possible by pharmacophore-based drug design and understanding in-silico methodologies.

Objective: The aim of the current investigation was to find novel 2-chloroquinoline-3-carboxamide derivatives that target the Ephrin B4 (EPHB4) receptor to treat cancer.

Materials and Methods: Chem Axon Marvin Sketch 5.11.5 was used to create derivatives of 2-chloroquinoline-3-carboxamide. The physicochemical characteristics of compounds as well as their toxicity were predicted using SwissADME& the admet SAR online software’s. Molecular docking technology was used to examine the ligand-receptor interactions of 2-chloroquinoline-3-carboxamide derivatives with the target receptor (PDB- 6FNM) using a variety of software’s, including Autodock1.1.2,Procheck, ProtParam tool, Biovia Discovery Studio Visualizer v20.1.0.19295, MGL Tools 1.5.6, PyMOL, and were all included.

Results: All developed compounds were determined to be orally bioavailable, less toxic, and have acceptable pharmacokinetic properties according to in silico studies. In comparison to the traditional medication Erdafitnib, all new compounds displayed higher docking scores.

Conclusion: The increase in binding energy and the number of H-bonds created by novel derivatives with interactions at distances below 3.40A provide a helpful starting point for formulating and synthesizing compounds that are most suitable for additional research. The application of the 2- chloroquinoline-3-carboxamide moiety as a potential new cancer treatment candidate is supported by its pharmacokinetics &toxicological profile, which may aid medicinal chemists in conducting more in-depth in vitro, in vivo chemical and pharmacological studies.

Keywords: EPHB4, Molecular docking, Pharmacokinetics, H-bond, Binding affinity, Toxicological.

[1]
Ferlay, J.; Ervik, M.; Lam, F.; Colombet, M.; Mery, L.; Piñeros, M. Global cancer observatory: Cancer today; International Agency for Research on Cancer: Lyon, France, 2020.
[http://dx.doi.org/10.1002/ijc.33588]
[2]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[3]
Nia, H.T.; Munn, L.L.; Jain, R.K. Physical traits of cancer. Science, 2020, 370(6516), eaaz0868.
[http://dx.doi.org/10.1126/science.aaz0868] [PMID: 33122355]
[4]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33.
[http://dx.doi.org/10.3322/caac.21708] [PMID: 35020204]
[5]
Nagai, H.; Kim, Y.H. Cancer prevention from the perspective of global cancer burden patterns. J. Thorac. Dis., 2017, 9(3), 448-451.
[http://dx.doi.org/10.21037/jtd.2017.02.75] [PMID: 28449441]
[6]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[7]
Bejarano, L.; Jordāo, M.J.C.; Joyce, J.A. Therapeutic targeting of the tumor microenvironment. Cancer Discov., 2021, 11(4), 933-959.
[http://dx.doi.org/10.1158/2159-8290.CD-20-1808] [PMID: 33811125]
[8]
Jia, Q.; Wang, A.; Yuan, Y.; Zhu, B.; Long, H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp. Hematol. Oncol., 2022, 11(1), 24.
[http://dx.doi.org/10.1186/s40164-022-00277-y] [PMID: 35461288]
[9]
Hayes, J.D.; Dinkova-Kostova, A.T.; Tew, K.D. Oxidative stress in cancer. Cancer Cell, 2020, 38(2), 167-197.
[http://dx.doi.org/10.1016/j.ccell.2020.06.001] [PMID: 32649885]
[10]
Verma, C.; Quraishi, M.A.; Ebenso, E.E. Quinoline and its derivatives as corrosion inhibitors: A review. Surf. Interfaces, 2020, 21, 100634.
[http://dx.doi.org/10.1016/j.surfin.2020.100634]
[11]
Abdelaziz, A.; Vaishampayan, U. Cabozantinib for the treatment of kidney cancer. Expert Rev. Anticancer Ther., 2017, 17(7), 577-584.
[http://dx.doi.org/10.1080/14737140.2017.1344553] [PMID: 28633552]
[12]
Fiorillo, M.; Lamb, R.; Tanowitz, H.B.; Cappello, A.R.; Martinez-Outschoorn, U.E.; Sotgia, F.; Lisanti, M.P. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging, 2016, 8(8), 1593-1607.
[http://dx.doi.org/10.18632/aging.100983] [PMID: 27344270]
[13]
Kurzrock, R.; Sherman, S.I.; Ball, D.W.; Forastiere, A.A.; Cohen, R.B.; Mehra, R.; Pfister, D.G.; Cohen, E.E.W.; Janisch, L.; Nauling, F.; Hong, D.S.; Ng, C.S.; Ye, L.; Gagel, R.F.; Frye, J.; Müller, T.; Ratain, M.J.; Salgia, R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol., 2011, 29(19), 2660-2666.
[http://dx.doi.org/10.1200/JCO.2010.32.4145] [PMID: 21606412]
[14]
Markowitz, J.N.; Fancher, K.M. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy, 2018, 38(3), 357-369.
[http://dx.doi.org/10.1002/phar.2076] [PMID: 29283440]
[15]
Xuhong, J-C.; Qi, X-W.; Zhang, Y.; Jiang, J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am. J. Cancer Res., 2019, 9(10), 2103-2119.
[PMID: 31720077]
[16]
Zhang, X.; Munster, P.N. New protein kinase inhibitors in breast cancer: Afatinib and neratinib. Expert Opin. Pharmacother., 2014, 15(9), 1277-1288.
[http://dx.doi.org/10.1517/14656566.2014.913570] [PMID: 24787047]
[17]
Mhaske, G.S.; Sen, A.K.; Shah, A.; Khiste, R.H.; Dale, A.V.; Sen, D.B. In silico identification of novel quinoline-3-carboxamide derivatives targeting platelet-derived growth factor receptor. Curr. Cancer Ther. Rev., 2022, 18(2), 131-142.
[http://dx.doi.org/10.2174/1573394718666220421111546]
[18]
Gouirand, V.; Gicquel, T.; Lien, E.C.; Jaune-Pons, E.; Da Costa, Q.; Finetti, P.; Metay, E.; Duluc, C.; Mayers, J.R.; Audebert, S.; Camoin, L.; Borge, L.; Rubis, M.; Leca, J.; Nigri, J.; Bertucci, F.; Dusetti, N.; Iovanna, J.L.; Tomasini, R.; Bidaut, G.; Guillaumond, F.; Vander Heiden, M.G.; Vasseur, S. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. EMBO J., 2022, 41(9), e110466.
[http://dx.doi.org/10.15252/embj.2021110466] [PMID: 35307861]
[19]
Rashid, H.; Xu, Y.; Muhammad, Y.; Wang, L.; Jiang, J. Research advances on anticancer activities of matrine and its derivatives: An updated overview. Eur. J. Med. Chem., 2019, 161, 205-238.
[http://dx.doi.org/10.1016/j.ejmech.2018.10.037] [PMID: 30359819]
[20]
Qiao, L.; Choi, S.; Case, A.; Gainer, T.G.; Seyb, K.; Glicksman, M.A.; Lo, D.C.; Stein, R.L.; Cuny, G.D. Structure–activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(21), 6122-6126.
[http://dx.doi.org/10.1016/j.bmcl.2009.09.010] [PMID: 19783434]
[21]
Unzue, A.; Lafleur, K.; Zhao, H.; Zhou, T.; Dong, J.; Kolb, P.; Liebl, J.; Zahler, S.; Caflisch, A.; Nevado, C. Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation. Eur. J. Med. Chem., 2016, 112, 347-366.
[http://dx.doi.org/10.1016/j.ejmech.2016.01.057] [PMID: 26907157]
[22]
Murad, H.; Hawat, M.; Ekhtiar, A.; AlJapawe, A.; Abbas, A.; Darwish, H.; Sbenati, O.; Ghannam, A. Induction of G1-phase cell cycle arrest and apoptosis pathway in MDA-MB-231 human breast cancer cells by sulfated polysaccharide extracted from Laurencia papillosa. Cancer Cell Int., 2016, 16(1), 39.
[http://dx.doi.org/10.1186/s12935-016-0315-4] [PMID: 27231438]
[23]
Luo, Y.; Yang, Y.; Peng, P.; Zhan, J.; Wang, Z.; Zhu, Z.; Zhang, Z.; Liu, L.; Fang, W.; Zhang, L. Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. Transl. Lung Cancer Res., 2021, 10(1), 128-142.
[http://dx.doi.org/10.21037/tlcr-20-812] [PMID: 33569299]
[24]
Dervisis, N.; Klahn, S. Therapeutic innovations: Tyrosine kinase inhibitors in cancer. Vet. Sci., 2016, 3(1), 4.
[http://dx.doi.org/10.3390/vetsci3010004] [PMID: 29056714]
[25]
El-Mesery, M.; Seher, A.; El-Shafey, M.; El-Dosoky, M.; Badria, F.A. Repurposing of quinoline alkaloids identifies their ability to enhance doxorubicin-induced sub-G0/G1 phase cell cycle arrest and apoptosis in cervical and hepatocellular carcinoma cells. Biotechnol. Appl. Biochem., 2021, 68(4), 832-840.
[http://dx.doi.org/10.1002/bab.1999] [PMID: 32757395]
[26]
Liang, X.; Wu, Q.; Luan, S.; Yin, Z.; He, C.; Yin, L.; Zou, Y.; Yuan, Z.; Li, L.; Song, X.; He, M.; Lv, C.; Zhang, W. A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. Eur. J. Med. Chem., 2019, 171, 129-168.
[http://dx.doi.org/10.1016/j.ejmech.2019.03.034] [PMID: 30917303]
[27]
Álvarez-Caballero, J.M.; Cuca-Suárez, L.E.; Coy-Barrera, E. Bio-guided fractionation of ethanol extract of leaves of esenbeckia alata kunt (Rutaceae) led to the isolation of two cytotoxic quinoline alkaloids: evidence of selectivity against leukemia cells. Biomolecules, 2019, 9(10), 585.
[http://dx.doi.org/10.3390/biom9100585] [PMID: 31597257]
[28]
Patel, R.; Chudasama, R.; Solanki, R.; Patel, P.; Parmar, K.; Munshi, N.S. Structure prediction and molecular docking studies of aromatic hydrocarbon sensing proteins TbuT, HbpR and PhnR to detect priority pollutants. J. Environ. Sci. Health Part A Tox. Hazard. Subst. Environ. Eng., 2020, 55(2), 126-141.
[http://dx.doi.org/10.1080/10934529.2019.1672457] [PMID: 31566066]
[29]
Bhattacharya, D.; Nowotny, J.; Cao, R.; Cheng, J. 3Drefine: An interactive web server for efficient protein structure refinement. Nucleic Acids Res., 2016, 44(W1), W406-W409.
[http://dx.doi.org/10.1093/nar/gkw336] [PMID: 27131371]
[30]
Ubhi, T.; Brown, G.W. Exploiting DNA replication stress for cancer treatment. Cancer Res., 2019, 79(8), 1730-1739.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-3631] [PMID: 30967400]
[31]
Montagut, A.M. Recent advances in the pharmacological targeting of ubiquitin regulating enzymes in cancer; Seminars in Cell & Developmental Biology Elsevier, 2022.
[http://dx.doi.org/10.1016/j.semcdb.2022.02.007]
[32]
Colovos, C.; Yeates, T.O. Verification of protein structures: Patterns of nonbonded atomic interactions. Protein Sci., 1993, 2(9), 1511-1519.
[http://dx.doi.org/10.1002/pro.5560020916] [PMID: 8401235]
[33]
Anand Mariadoss, A.V.; Krishnan Dhanabalan, A.; Munusamy, H.; Gunasekaran, K.; David, E. In silico studies towards enhancing the anticancer activity of phytochemical phloretin against cancer drug targets. Curr. Drug Ther., 2018, 13(2), 174-188.
[http://dx.doi.org/10.2174/1574885513666180402134054]
[34]
Ikeda, F. Ubiquitin conjugating enzymes in the regulation of the autophagy-dependent degradation pathway. Matrix Biol., 2021, 100-101, 23-29.
[http://dx.doi.org/10.1016/j.matbio.2020.11.004] [PMID: 33276077]
[35]
Velusamy, S.; Husain, S.A.; Alarifi, S. Screening potential inhibitor from actinomycetes for dihydrofolate reductase of staphylococcus aureus–in vitro and in silico studies. J. King Saud Uni-Sci., 2023, 35(6), 102762.
[http://dx.doi.org/10.1016/j.jksus.2023.102762]
[36]
Becker, H.M. Carbonic anhydrase IX and acid transport in cancer. Br. J. Cancer, 2020, 122(2), 157-167.
[http://dx.doi.org/10.1038/s41416-019-0642-z] [PMID: 31819195]
[37]
Abner, E.; Stoszko, M.; Zeng, L.; Chen, H.C.; Izquierdo-Bouldstridge, A.; Konuma, T.; Zorita, E.; Fanunza, E.; Zhang, Q.; Mahmoudi, T.; Zhou, M.M.; Filion, G.J.; Jordan, A. A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for reactivation from other “shock” drugs. J. Virol., 2018, 92(10), e02056-17.
[http://dx.doi.org/10.1128/JVI.02056-17] [PMID: 29343578]
[38]
Umar, A. B.; Uzairu, A.; Shallangwa, G. A.; Uba, S. Design of potential anti-melanoma agents against SK-MEL-5 cell line using QSAR modeling and molecular docking methods. SN Applied Sciences, 2020, 2(5), 815.
[http://dx.doi.org/10.1007/s42452-020-2620-8]
[39]
Saeed, M.E.; Kadioglu, O.; Seo, E.J.; Greten, H.J.; Brenk, R.; Efferth, T. Quantitative structure-activity relationship and molecular docking of artemisinin derivatives to vascular endothelial growth factor receptor 1. Anticancer Res., 2015, 35(4), 1929-1934.
[PMID: 25862844]
[40]
Daina, A.; Zoete, V. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem, 2016, 11(11), 1117-1121.
[http://dx.doi.org/10.1002/cmdc.201600182] [PMID: 27218427]
[41]
Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep., 2017, 7(1), 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[42]
Gramatica, P.; Giani, E.; Papa, E. Statistical external validation and consensus modeling: A QSPR case study for Koc prediction. J. Mol. Graph. Model., 2007, 25(6), 755-766.
[http://dx.doi.org/10.1016/j.jmgm.2006.06.005] [PMID: 16890002]
[43]
Bingul, M.; Tan, O.; Gardner, C.; Sutton, S.; Arndt, G.; Marshall, G.; Cheung, B.; Kumar, N.; Black, D. Synthesis, characterization and anti-cancer activity of hydrazide derivatives incorporating a quinoline moiety. Molecules, 2016, 21(7), 916.
[http://dx.doi.org/10.3390/molecules21070916] [PMID: 27428941]
[44]
Venugopala, K.N.; Uppar, V.; Chandrashekharappa, S.; Abdallah, H.H.; Pillay, M.; Deb, P.K.; Morsy, M.A.; Aldhubiab, B.E.; Attimarad, M.; Nair, A.B.; Sreeharsha, N.; Tratrat, C.; Yousef Jaber, A.; Venugopala, R.; Mailavaram, R.P.; Al-Jaidi, B.A.; Kandeel, M.; Haroun, M.; Padmashali, B. Cytotoxicity and antimycobacterial properties of pyrrolo[1,2-a]quinoline derivatives: Molecular target identification and molecular docking studies. Antibiotics, 2020, 9(5), 233.
[http://dx.doi.org/10.3390/antibiotics9050233] [PMID: 32392709]
[45]
Shetty, P.R.; Shivaraja, G.; Krishnaswamy, G.; Pruthviraj, K.; Mohan, V.C.; Sreenivasa, S. Synthesis, characterization, biological screening, adme and molecular docking studies of 2-phenyl quinoline-4-carboxamide derivatives. Asian J. Chem., 2020, 32(5), 1151-1157.
[http://dx.doi.org/10.14233/ajchem.2020.22583]
[46]
Diaa, A.I.; Dalal, A.; Abou, E.E.; Amira, M.; Motwally, E.; Rasha, M.A. Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity. Eur. J. Med. Chem., 2015, 7, 30.
[http://dx.doi.org/10.1016/j.ejmech.2015.07.030]
[47]
Attique, S.; Hassan, M.; Usman, M.; Atif, R.; Mahboob, S.; Al-Ghanim, K.; Bilal, M.; Nawaz, M. A molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension. Int. J. Environ. Res. Public Health, 2019, 16(6), 923.
[http://dx.doi.org/10.3390/ijerph16060923] [PMID: 30875817]
[48]
Abdullahi, M.; Shallangwa, G.A.; Uzairu, A. Insilico QSAR and molecular docking simulation of some novel aryl sulfonamide derivatives as inhibitors of H5N1 influenza A virus subtype. Beni. Suef Univ. J. Basic Appl. Sci., 2020, 2(9), 1-12.
[http://dx.doi.org/10.1186/s43088-019-0023-y]
[49]
Ashan, M.J.; Yadav, R.; Jadhav, S.S. Synthesis, Anticancer activity and Molecular docking studies of newer quinoline analogues. 1stInternational electronic conference on Medicinal chemistry, 2015, 1-14.
[http://dx.doi.org/10.3390/ecmc-1-A033]
[50]
Abdullahi, M.; Adeniji, S.E. In-silico molecular docking and ADME/pharmacokinetic prediction studies of some novel carboxamide derivatives as anti-tubercular agents. Chemistry Africa, 2020, 3(4), 989-1000.
[http://dx.doi.org/10.1007/s42250-020-00162-3]
[51]
Wang, G.; Bai, Y.; Cui, J.; Zong, Z.; Gao, Y.; Zheng, Z. Computer-aided drug design boosts RAS inhibitor discovery. Molecules, 2022, 27(17), 5710.
[http://dx.doi.org/10.3390/molecules27175710] [PMID: 36080477]
[52]
Zhong, S.; Hou, Y.; Zhang, Z.; Guo, Z.; Yang, W.; Dou, G.; Lv, X.; Wang, X.; Ge, J.; Wu, B.; Pan, X.; Wang, H.; Yang, Q.; Mou, Y. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study. Bioengineered, 2022, 13(5), 12003-12020.
[http://dx.doi.org/10.1080/21655979.2021.2011631] [PMID: 35603567]
[53]
Mokhtar, M.; Alghamdi, K.S.; Ahmed, N.S.; Bakhotmah, D.; Saleh, T.S. Design and green synthesis of novel quinolinone derivatives of potential anti-breast cancer activity against MCF-7 cell line targeting multi-receptor tyrosine kinases. J. Enzyme Inhib. Med. Chem., 2021, 36(1), 1453-1470.
[http://dx.doi.org/10.1080/14756366.2021.1944126] [PMID: 34210212]
[54]
Martorana, A.; La Monica, G.; Lauria, A. Quinoline-based molecules targeting c-met, EGF, and VEGF receptors and the proteins involved in related carcinogenic pathways. Molecules, 2020, 25(18), 4279.
[http://dx.doi.org/10.3390/molecules25184279] [PMID: 32961977]
[55]
Govender, H.; Mocktar, C.; Koorbanally, N.A. Synthesis and Bioactivity of Quinoline-3- carboxamide Derivatives; J. Heterocyclic Chem, 2018.
[http://dx.doi.org/10.1002/jhet.3132]
[56]
Teli, M.K.; Rajanikant, G.K. Pharmacophore generation and atom-based 3D-QSAR of novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors. J. Enzyme Inhib. Med. Chem., 2012, 27(4), 558-570.
[http://dx.doi.org/10.3109/14756366.2011.603128] [PMID: 21851209]
[57]
Ayati, A.; Moghimi, S.; Salarinejad, S.; Safavi, M.; Pouramiri, B.; Foroumadi, A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg. Chem., 2020, 99, 103811.
[http://dx.doi.org/10.1016/j.bioorg.2020.103811] [PMID: 32278207]
[58]
Bolakatti, G.; Palkar, M.; Katagi, M.; Hampannavar, G.; Karpoormath, R.V.; Ninganagouda, S.; Badiger, A. Novel series of benzo[d]thiazolyl substituted-2-quinolone hybrids: Design, synthesis, biological evaluation and in-silico insights. J. Mol. Struct., 2021, 1227, 129413.
[http://dx.doi.org/10.1016/j.molstruc.2020.129413]
[59]
Deaton, D.N.; Do, Y.; Holt, J.; Jeune, M.R.; Kramer, H.F.; Larkin, A.L.; Orband-Miller, L.A.; Peckham, G.E.; Poole, C.; Price, D.J.; Schaller, L.T.; Shen, Y.; Shewchuk, L.M.; Stewart, E.L.; Stuart, J.D.; Thomson, S.A.; Ward, P.; Wilson, J.W.; Xu, T.; Guss, J.H.; Musetti, C.; Rendina, A.R.; Affleck, K.; Anders, D.; Hancock, A.P.; Hobbs, H.; Hodgson, S.T.; Hutchinson, J.; Leveridge, M.V.; Nicholls, H.; Smith, I.E.D.; Somers, D.O.; Sneddon, H.F.; Uddin, S.; Cleasby, A.; Mortenson, P.N.; Richardson, C.; Saxty, G. The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors. Bioorg. Med. Chem., 2019, 27(8), 1456-1478.
[http://dx.doi.org/10.1016/j.bmc.2019.02.017] [PMID: 30858025]
[60]
Santosh, K.; Aghara, J.C.; Alex, A.T.; Aranjani, A.M.; Alex, J. Novel quinolone substituted quinazolin-4(3H)-Ones as anti-inflammatory, anti-cancer agents: Synthesis and biological screening.. Indian J. Pharm. Edu. and Res., 2018, 4(52-2), 268-276.
[http://dx.doi.org/10.5530/ijper.52.4s.107]
[61]
Pucci, C.; Martinelli, C.; Ciofani, G. Innovative approaches for cancer treatment: Current perspectives and new challenges. Ecancermedicalscience, 2019, 13, 961.
[http://dx.doi.org/10.3332/ecancer.2019.961] [PMID: 31537986]
[62]
Abbas, Z.; Rehman, S. An overview of cancer treatment modalities. Neoplasm., 2018, 1, 139-157.
[http://dx.doi.org/10.5772/intechopen.76558]
[63]
Guo, L.J.; Wei, C.X.; Jia, J.H.; Zhao, L.M.; Quan, Z.S. Design and synthesis of 5-alkoxy-[1,2,4]triazolo[4,3-a]quinoline derivatives with anticonvulsant activity. Eur. J. Med. Chem., 2009, 44(3), 954-958.
[http://dx.doi.org/10.1016/j.ejmech.2008.07.010] [PMID: 18752871]
[64]
Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H.W.H.; Neefs, J.M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707), 223-227.
[http://dx.doi.org/10.1126/science.1106753] [PMID: 15591164]
[65]
Priscilla, J.; Arul Dhas, D.; Hubert Joe, I.; Balachandran, S. Experimental and theoretical spectroscopic analysis, hydrogen bonding, reduced density gradient and antibacterial activity study on 2-Phenyl quinoline alkaloid. Chem. Phys., 2020, 536, 110827.
[http://dx.doi.org/10.1016/j.chemphys.2020.110827]
[66]
Rout, P.K.; Kumar, P.; Rao, Y.R.; Kumar, A.; Bawankule, D.U.; Singh, R.; Singh, K.B.; Chanotiya, C.S.; Naik, S.N. A quinoline alkaloid rich Quisqualis indica floral extract enhances the bioactivity. Nat. Prod. Res., 2021, 35(10), 1632-1638.
[http://dx.doi.org/10.1080/14786419.2019.1634709] [PMID: 31264476]
[67]
Shaldam, M.; Nocentini, A.; Elsayed, Z.M.; Ibrahim, T.M.; Salem, R.; El-Domany, R.A.; Capasso, C.; Supuran, C.T.; Eldehna, W.M. Development of novel quinoline-based sulfonamides as selective cancer-associated carbonic anhydrase isoform IX inhibitors. Int. J. Mol. Sci., 2021, 22(20), 11119.
[http://dx.doi.org/10.3390/ijms222011119] [PMID: 34681794]
[68]
Lauria, A.; La Monica, G.; Bono, A.; Martorana, A. Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets. Eur. J. Med. Chem., 2021, 220, 113555.
[http://dx.doi.org/10.1016/j.ejmech.2021.113555] [PMID: 34052677]
[69]
Hamdy, R.; Elseginy, S.; Ziedan, N.; Jones, A.; Westwell, A. New quinoline-based heterocycles as anticancer agents targeting bcl-2. Molecules, 2019, 24(7), 1274.
[http://dx.doi.org/10.3390/molecules24071274] [PMID: 30986908]
[70]
Li, W.; Shuai, W.; Sun, H.; Xu, F.; Bi, Y.; Xu, J.; Ma, C.; Yao, H.; Zhu, Z.; Xu, S. Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site. Eur. J. Med. Chem., 2019, 163, 428-442.
[http://dx.doi.org/10.1016/j.ejmech.2018.11.070] [PMID: 30530194]
[71]
Díaz, I.; Salido, S.; Nogueras, M.; Cobo, J. Design and synthesis of new pyrimidine-quinolone hybrids as novel hldha inhibitors. Pharmaceuticals, 2022, 15(7), 792.
[http://dx.doi.org/10.3390/ph15070792] [PMID: 35890090]
[72]
Patrício, R.P.S.; Videira, P.A.; Pereira, F. A computer-aided drug design approach to discover tumour suppressor p53 protein activators for colorectal cancer therapy. Bioorg. Med. Chem., 2022, 53, 116530.
[http://dx.doi.org/10.1016/j.bmc.2021.116530] [PMID: 34861473]